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1. Introduction
   Diabetes mellitus is the most significant chronic disease 
and a growing health problem in most countries[1-3]. It is 
due to lack of insulin secretion in β- cells of pancreas and 
desensitization of insulin receptors for insulin[4]. It causes a 
number of complications such as retinopathy, neuropathy, 
and peripheral vascular insufficiencies[2]. Most patients 
with type-2 diabetes have insulin resistance and this is 
predisposing to both diabetes and cardiovascular disease[3]
which usually results from high level of glucose in the blood 
and byproducts of lipid metabolism within the tissues[4]. 
Many oral hypoglycemic agents, such as biguanides 
and sulfonylurea are available along with insulin for the 
treatment of diabetes mellitus but these synthetic agents can 
produce serious side-effects, and in addition, they are not 
suitable for use during pregnancy[5,6]. Recently, the search 
for appropriate antihyperglycemic agents has been focused 
on the types of natural food products used in traditional 
medicine. Many traditional medicinal herb extracts have 
been used for the treatment of diabetes mellitus due to 
lower side effects. Many researchers have shown that 
cinnamon extract has a moderate effect in reducing fasting 
plasma glucose concentrations in both diabetic patients 
and animals[7-10]. The active compounds of cinnamon have 
been reported, such as water-soluble polyphenol type-A 
polymers[11,12], cinnamaldehyde[13], and cinnamic acid[14].
   Cinnamomum bejolghota (Buch.-Ham.) (C. bejolghota) is a 
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medium- to large-sized evergreen tree with aromatic leaves, 
stem bark and panicle, and distributed in the central and 
outer parts of eastern Himalayas up to an altitude of 2 100 
m, and also in Andaman Islands. In Assam the plant is well 
distributed in the Jorhat, Sibsagar, Golaghat, Nowgaon and 
Kamrup districts. It also grows in the Khasi, Garo and Jaintia 
districts of Meghalaya and in a few places of Nagaland 
in northeast India[15]. The bark, which is sold at the local 
markets, is used traditionally in the region as a spice. The 
bark and its infusions have local medicinal use for the 
treatment of a cough, cold, toothache, liver complaints, 
diabetes, gall stones and are used as a mouth freshener. In 
contrast, the leaves have been in use among some of the 
ethnic societies for preparation of a special kind of rice-beer 
known as “Apong”[16]. Work has been carried out with the 
methanolic bark extract of C. bejolghota (MECB) with a view 
to investigate its anti-diabetic potential in streptozotocin 
(STZ) induced type-2 diabetic rats against metformin as a 
standard drug.
2. Materials and methods
2.1. Chemicals and diagnostic kits
   STZ, ethyl ether, ethylenediaminetetraacetic acid disodium 
salt, n-butyl alcohol, pyridine, reduced glutathione (Sisco 
Research Laboratories Pvt. Ltd., Mumbai, India), carboxy 
methyl cellulose, acetic acid, tris buffer (Rankem Chemicals, 
Faridabad, India), metformin (Sigma- Aldrich Chemical 
Company, St. Louis, M.O, USA), potassium dihydrogen 
phosphate, disodium hydrogen phosphate, thiobarbituric 
acid (HiMedia Labotratory, Mumbai, India), hydrogen 
peroxide (Loba Chemie Pvt. Ltd., Mumbai, India), 5,5-
dithiobis (2-nitrobenzoic acid), sodium dodecyl sulphate 
(Otto Chemie Pvt. Ltd., Mumbai, India), trichloroacetic 
acid (Qualikems fine chemicals P. Ltd., New Delhi, India), 
potassium chloride (Spectrochem Pvt. Ltd., Mumbai, India), 
one-touch glucometer accucheck (Roche products, Pvt. Ltd., 
Bayer Diagnostics, Mumbai, India), alkaline phosphatase 
(ALP) kit, total cholesterol kit, high density cholesterol 
(HDL) kit, triglyceride kit, alanine transaminase (SGPT) Kit, 
aspartate transaminase (SGOT) kit (Span Diagnostics Pvt. Ltd., 
Surat, India) were used in this study.
2.2. Collection of plant material and preparation of 
methanolic extract obtained from the plant bark 
   The bark of C. bejolghota (Buch.-Ham.) was collected from 
Rowriah, Jorhat, Assam, India during the month of July, 
2013. The plant was identified and authenticated by Dr. A.A. 
Mao, Botanical Survey of India, Eastern Regional Centre, 
Shillong. A voucher specimen (specimen No. DU/CB/2014/07, 
reference No. (BSI/ERC/2014/Plant identification/882) is kept 
in Department of Pharmaceutical Sciences, Dibrugarh 
University, Assam for future references. Barks were cut 
into pieces, washed thoroughly with water and then dried 
partially under sunlight and partially under the shade for 
a week. The dried bark pieces were then pulverized in a 
mechanical grinder to coarse powder and then stored in 
airtight containers free from moisture.
   Powdered crude drug (250 g) of C. bejolghota bark were 
extracted by Soxhlation (Continuous hot extraction) with 1 000 
mL of methanol for 18 h after pretreatment with petroleum 
ether. The solvent was recovered at 50 °C by distillation 
under reduced pressure and the extract was concentrated 
to obtain an orange brown semisolid mass. Preliminary 
phytochemical tests were carried out with all the extracts in 
order to evaluate for the presence of different phytochemical 
constituents. The methanolic extract of the bark of C. 
bejolghota (MECB) contains flavanoids, carbohydrates, 
glycosides, lignin, steroids, saponins, tannins and phenolic 
compounds.
2.3. Drugs
   Methanolic bark extract of C. bejolghota (250 and 500 mg/
kg of body weight), metformin (10 mg/kg of body weight per 
orally) were used in the experiment.
2.4. Selection and maintenance of animals
   Male albino rats of Wistar strain, weighing about 100-200 
g were obtained from M/S Chakraborty Enterprise, Kolkata 
and used for the experimental study. The required approval 
for performing the animal study was acknowledged from 
the Institutional Animal Ethical committee, Dibrugarh 
University, vide registration number-1576/GO/a/11/CPCSEA 
dated 17/2/2012, and approval number-IAEC/DU/59 dated: 
24/9/2013.
   The animal house was well ventilated and maintained 
at room temperature from (20依2) °C to (25依2) °C, 30%-35% 
of relative humidity and 12 h dark/light cycle. They were 
housed in large spacious hygienic cages during the course 
of the experimental period and were provided with pellet 
diet (Hindustan lever, Mumbai, India) and water ad libitum.
Prior to the experimental study, animals were fasted by 
depriving them of food for 16 h but allowing free access to 
water. The place of experiment was kept very hygienic by 
cleansing with antiseptic solution, and further procedures 
involving care of animals was conducted in conformity with 
the institutional guidelines.
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2.5. Acute toxicity study
   Healthy adult male Wistar rats were starved overnight 
and divided into five groups containing five animals in each 
group (n=5). They were orally fed with MECB dissolved in 
0.5% carboxy methylcellulose in increasing dose levels of 
500, 1 000, 1 500, 2 000, 2 500 mg/kg. The animals were observed 
continuously for 2 h and then for 4 h under behavioral (gross 
behavior, writhing, convulsion, response to tail pinching, 
pupil size, itching, excessive salivation, urination, faecal 
output, water intake, feeding behavior, sedation etc.), 
neurological and autonomic profiles. After a period of 24 
and 72 h, they were observed for any lethality or death and 
further kept under observation up to 15 d. The effective dose 
of the MECB was determined to be 1/10th of the maximum 
dose which is 2 500 mg/kg[17].
2.6. Oral glucose tolerance test (OGTT)
   Initial screening of the extract for the hypoglycemic 
activity was done in normal healthy rats by conducting OGTT. 
The OGTT was performed for two different doses of MECB (250 
and 500 mg/kg of bodyweight per orally) and blood glucose 
level was measured by one touch glucometer (accu-check). 
The glucose level was measured at the intervals of 0, 30, 60, 
90 and 120 min after the administration of extract[18].
2.7. Induction of experimental diabetes
   After overnight fasting, type 2 diabetes was induced by 
intraperitoneal injection of STZ dissolved in 0.1 mol/L cold 
citrate buffer, pH 4.5, at a dose of 55 mg/kg of body weight. 
The control rats received the vehicle alone. After 1 week 
diabetes was developed. The rats with moderate diabetes 
having glycosuria and hyperglycemia (blood glucose range of 
above 250 mg/dl) were considered as diabetic rats and used 
for the experiment.
2.8. Experimental design
   The experimental rats were divided into five groups with 
5 rats for each. Group-I was administered with 0.5% carboxy 
methylcellulose 5 mL/kg body weight orally as normal control. 
Group-II was received 55 mg/kg body weight STZ with 
diabetic control rats. Group-III was treated orally once a 
day for 15 d with MECB, 250 mg/kg body weight and served 
as low dose. Group-IV was treated orally once a day for 15 
d with MECB, 250 mg/kg body weight and served as high 
dose. Group-V was treated orally once a day for 15 d with 
metformin 10 mg/kg of body weight and served as standard 
control.
   Blood samples were collected from the tail vein of the 
overnight (12-15 h) fasted rats and blood glucose level 
was determined on 0th, 5th,10th and 15th d. On the 15th 
day all the animals were sacrificed and evaluated for 
the biochemical parameters, histopathology and in vivo 
antioxidative status[19].
2.9. Biochemical estimations
   After 15 d of treatment, the animals were fasted for 15 
h and then sacrificed by cervical decapitation. Blood 
was collected in the tubes containing ethylene diamine 
tetraacetic acid as anticoagulant for the estimations of total 
cholesterol, HDL, low density lipoprotein (LDL), triglycerides, 
in plasma and SGOT, SGPT, ALP levels were estimated in 
serum that was collected separately. These parameters were 
measured in a colorimeter.  
2.10. In vivo antioxidative status
   A portion of the liver tissue was dissected out, washed with 
ice cold saline immediately and kept at 4 °C. The following 
methods were performed as follows.
2.10.1. Lipid peroxidation
   Lipid peroxidation was estimated by the method of 
Ohkawa[20]. UV spectrphotometer of model No. SPECORD 
® 50 PLUS Analytikjena was used. The levels of lipid 
peroxides were expressed as nmole of thiobarbituric acid-
reacting substances/mg protein using extinction co-
efficient of 1.56伊105 L/mol.cm.
2.10.2. Reduced glutathione level
   Reduced glutathione was estimated spectrophotometrically 
by determination of dithiobis (2-nitrobenzoicacid) reduced 
by sulfhydryl-groups, as described by Mulder and expressed 
as nmol/mg protein[21]. Outside diameter was read [within 
2-3 min after the addition of 5,5’-dithiobis-(2-nitrobenzoic 
acid)] at 412 nm in UV Spectrophotometer of model No. 
SPECORD ® 50 PLUS Analytikjena against a reagent blank. 
Appropriate standards were run simultaneously.
2.10.3. Catalase activity
   Catalase activity was measured based on the ability of the 
enzyme to break down H2O2. Sample with 10 µL was taken 
in tube containing 3.0 mL of H2O2 in phosphate buffer. Time 
required for 0.05 optical density changes was observed 
at 240 nm against a blank containing the enzyme source 
in H2O2 free phosphate buffer [0.16 mL H2O2 (30% w/v) was 
diluted to 100 mL of phosphate buffer]. The absorbance 
was noted at 240 nm after the addition of enzyme; Δt was 
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noted till outside diameter was 0.45. If Δt was longer 
than 60 seconds, the procedure was repeated with more 
concentrated enzyme sample. Reading was taken at every 
3 seconds interval. A unit catalase activity is the amount 
of enzyme that liberates half of the oxygen peroxide from 
H2O2 solution of any concentration in 100 seconds at 25 °C. 
Catalase activity is expressed as follows[22]. 
   Moles of H2O2 consumed/min (Units/mg protein)=2.3/Δt伊In 
(E initial/E final)伊1.63伊10-3
   where E is optical density at 240 nm; 2.3 is factor to convert 
in to log; Δt refers to time required for a decrease in the 
absorbance.
2.11. Histopathological study
2.11.1 Tissue preparation for histology
   After sacrificing the rats by cervical decapitation, 
pancreatic tissues were collected, washed in normal saline 
and fixed by using fixative (picric acid, formaldehyde 40% 
and glacial acetic acid) for 24 h and dehydrated with alcohol. 
All tissues were cleaned and embedded by using xylene 
and paraffin (melting point 55-60 °C). Tissues were stained 
by double staining process. To differentiate the nucleus and 
cytoplasm, the basic due haematoxylin and the acid dye 
eosin were used[23]. Electron micrographs were performed 
using transmission electron microscope and photographed 
by photomicrography.
2.12. Statistical analysis
   All result was expressed as the mean依SEM using One-way 
Analysis of Variance (ANOVA) followed by Dunnett’s tests. 
The software used was Graph Pad Prism version 6 (Graph Pad 
Software Inc., La Jolla, CA, USA). The results are analyzed for 
statistical significance and significance was expressed by 
P value, as mention in the tables. P<0.01 was considered as 
statistically significant.
3. Results
3.1. Effect of treatment on general parameters
   Changes in various physical parameters like the body 
weight, blood glucose level, biochemical estimations were 
studied in normal controls, STZ induced untreated and 
treated (with MECB 250 mg/kg b.w., MECB 500 mg/kg b.w. and 
standard metformin) diabetic rats.
3.2. Effect of MECB on oral glucose tolerance in normal mice
   In OGTT test the blood glucose levels of control group 
reached a peak increased at 30 min and then increased 
continuously to attain a basal glucose level. Dose dependent 
blood glucose reduction was observed in animals treated 
with 250 mg/kg and 500 mg/kg at 60, 90 and 120 min. All 
the doses showed significant reduction in blood glucose 
(
**P<0.01) when compared to control (Table 1).
Table 1
Oral glucose tolerance test. mg/dL.
Animal group 0 min 30 min 60 min 90 min 120 min
Group-I 77.000依0.547  141.400依0.927 152.6依1.122 162.800依0.969  181.600依1.435
Group-II 79.200依1.319  101.600依3.473** 101.2依1.715**   94.400依0.748**    84.200依2.782**
Group-III 80.000依0.836  111.000依1.871** 102.2依2.538**   92.000依0.836**    81.200依0.734**
Values are expressed as mean依SEM (n=5); Statistical significance: *: P<0.05; 
**: P<0.01, compared with Group-I.  
3.3. Effect of MECB on body weight
   The body weight of STZ-induced diabetic rats decreased 
gradually; on the other hand, the animals of test groups 
showed signs of improvement in their body weights 
progressively during 15 d treatment except on the 5th and 
10th day. The standard group (Group-V) animals showed 
improvement in their body weights gradually as compared 
with normal control group (Group-I) (Table 2). In diabetic 
control group (Group-II), body weight decreased gradually 
throughout the 15 d experiment from (182.400依1.470) to 
(174.400依2.205) g. After administration of MECB (250 mg/kg 
b.w.) there was a slight increase in body weight from (191.400
依2.462) to (192.800依2.683) g and after the administration of 
high dose (500 mg/kg), body weight increased from (182.600依
2.750)  to (186.200依2.634) g during the 15 d treatment. Standard 
treated group (Group-V), showed increase in body weight 
from (170.600依2.804) g on 0th day to (175.800依4.306) g on 15th 
day.
Table 2
The deviation of body weight of the animals during the treatment of MECB 
during 15 days of treatment. mg/dL.
Animal group 0th day 5th day 10th day 15th day
Group-I 190.600依2.804##  191.600依2.804## 192.600依0.390## 195.600依2.205##
Group-II 182.400依1.470#  181.200依1.594* 176.600依2.337** 174.400依2.205**
Group-III 191.400依2.462##  190.000依2.739## 191.600依2.619## 192.800依2.683##
Group-IV 182.600依2.750##   181.200依02.245* 185.000依2.510 186.200依2.634
Group-V 170.600依2.804**  171.000依3.674** 174.000依4.000** 175.800依4.306**
Values are expressed as  mean依SEM (n=5); Statistical significance: *: P<0.05; 
**: P<0.01, compared with that of normal control Group-I; #: P<0.05; ##: 
P<0.01, compared with standard Group-V. 
3.4. Effect of MECB on blood glucose level
   In Group-II, blood glucose level of animals increased 
gradually throughout the 15 days experiment from 242.600 to 
270.000 mg/dL. After administration of MECB (250 mg/kg b.w.) 
there was a decrease in blood glucose level from 242.400 
to 135.200 mg/dL in Group-III, but after the administration 
of high dose (500 mg/kg) blood glucose level decreased 
from 234.000 to 123.800 mg/dL in Group-IV during the 15 d 
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treatment. Group-V showed a drastic fall in blood glucose 
level from (240.000依2.739) mg/dL on 0th day to (113.2依1.200) 
mg/dL on 15th day (Table 3, Figure 1). 
Table 3 
The effect of MECB on fasting blood glucose level on STZ-induced diabetic 
rats. mg/dL.
Treatment 0th day 5th day 10th day 15th day
Group-I 92.530依0.447 102.000依0.547## 102.600依1.070## 96.400依0.670##
Group-II  242.600依1.122**    264.800依1.463**##   270.000依2.230**##   270.000依0.540**##
Group-III  242.400依1.122**    177.400依1.122**##   173.800依1.590**##   135.200依1.463**##
Group-IV  234.000依1.871**  160.800依1.855**   132.000依0.890**##   123.800依2.035**##
Group-V  240.000依2.739**  164.000依1.871** 132.600依1.120** 113.200依1.200**
Values are mean依SEM (n=5); Statistical significance: *: P<0.05; **: P<0.01, 
compared with Group-I; #: P<0.05; ##: P<0.01, compared with Group-V.
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Figure 1. Blood glucose level.
3.5. Effect of MECB on plasma lipid profiles and serum 
biomarkers
   Table 4 illustrates the effects of different doses (250 mg/
dl and 500 mg/dl) of MECB on the serum cholesterol, serum 
triglyceride, HDL and LDL levels in STZ-induced diabetic rats 
using metformin hydrochloride (10 mg/kg) as standard drug. 
In the present study, the total cholesterol, triglycerides and 
LDL cholesterol was increased in diabetic control groups 
and it was reduced in 15 d treatment with MECB but the HDL 
cholesterol level was significantly increased. On treatment 
with MECB there were decreased triglyceride and cholesterol 
levels compared to those of diabetic control Group-II. The 
HDL-cholesterol level increased and LDL cholesterol level 
decreased significantly as compared with diabetic control 
Group-II. 
Table 4
Effects of MECB on plasma lipid profiles (cholesterol, triglycerides, HDL, and 
LDL) in STZ-induced diabetic rats. mg/dL.
Groups Cholesterol Triglyceride HDL LDL
Group-I   158.200依0.916##  207.600依1.122##  41.000依2.300##  67.640依3.800##
Group-II   228.200依0.916**  300.200依0.916**  26.000依2.200** 137.530依4.200**
Group- III    172.600依1.122**##   236.400依1.568**##    32.172依 0.368#   91.500依1.200* ##
Group-IV    205.200依1.463**##   250.400依0.748**##  24.000依0.316**  122.420依1.993## **
Group-V    165.800依0.969**##   232.600依1.122**##  34.000依1.700 #  84.580依3.800*##
Values are mean依SEM (n=5); Statistical significance: *: P<0.05; **: P<0.01, 
compared with Group-I; #: P<0.05; ##: P<0.01, compared with Group-II.
3.6. Effect of MECB on in vivo antioxidant status
   The oxidative stress induced by STZ may lead to 
imbalance of in vivo antioxidant system and that was 
evaluated by this study. The oxidative stress in diabetic rats 
was measured by markers since free radical measurement 
was difficult due to their very short half-life and their low 
concentration shown in Table 5. 
Table 5
Effect of MECB on liver lipid peroxidation, glutathione and catalase enzymes 
in STZ-induced diabetic rats. 
Groups
Lipid peroxidation 
(nmol/L of MDA/mg 
of protein)
Glutathione  
(nmol/Lmg of protein)
Catalase 
(nmol/L of H2O2 
decomposed/min/mg)
Group-I     15.410依0.244##     50.800依0.800##       14.200依0.800##
Group-II     35.600依0.400**##     23.800依1.020**##         5.600依0.400**##
Group-III     27.400依0.400     35.200依0.800**         5.800依0.200**##
Group-IV     23.800依0.489**##       7.600依0.244**##         7.800依0.734**
Group-V     20.000依0.632**##      43.600依1.470**##         8.400依0.244**
Values are mean依SEM (n=5); Statistical significance: *: P<0.05; **: P<0.01, 
compared with Group-I; #: P<0.05; ##: P<0.01, compared with Group-V.
   Elevated lipid peroxidation was studied in STZ diabetic 
animals. Groups treated with MECB and metformin 
significantly reduced the oxidation of lipids in liver. 
   Total antioxidant status was measured by amount of 
enzymatic glutathione. Glutathione played the important 
role in balance the oxidative stress. In diabetic control 
groups, the decreased glutathione may be due to reduction 
in glutathione synthesis or degradation of glutathione 
by oxidation stress in diabetic animal. Diabetic group 
produced less glutathione activity whereas the standard 
drug showed reductase activity.
   Elevation of biomarker enzymes such as SGOT, SGPT, ALP 
were observed in diabetic group which indicated hepatic 
damage. On treatment with MECB the reduced levels of the 
elevated marker enzymes i.e. SGOT, SGPT, ALP had been 
restored to more or less normal values which indicated 
recovery of insulin secretion shown in Table 6. Hence MECB 
may act as an antihyperglycemic agent.
Table 6
Effect of MECB on serum biomarkers in STZ-induced diabetic rats. 
Groups SGOT SGPT ALP
Group-I 52.600依1.122## 40.800依0.969## 104.200依0.374##
Group-II 105.00依2.236** 82.400依0.748** 172.600依1.122**
Group-III     74.200依1.356 **##   62.600依1.122**##   135.000依1.095**##
Group-IV 55.600依1.122##   47.400依0.748**##   121.800依1.594**##
Group-V 51.800依0.916##   46.600依0.672**##   120.400依0.748**##
Values are mean依SEM (n=5); Statistical significance: *: P<0.05; **: P<0.01, 
compared with Normal control group I; #: P<0.05; ##: P<0.01, compared with 
Group-II.
   Catalase is an antioxidant enzyme produced naturally 
within the body. It helps the body to convert hydrogen 
peroxide into water and oxygen, thus preventing the 
formation of carbon dioxide bubbles in the blood. Catalase 
also uses hydrogen peroxide to break down potentially 
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harmful toxins in the body, including alcohol, phenol, and 
formaldehyde. It is a haem containing enzymes. The level of 
catalase was improved by MECB and metformin. The above 
in vivo antioxidant status is a support to antihyperglycemic 
effect of methanolic bark extract of C. bejolghota. 
3.7. Effect of MECB on histopathology
3.7.1. Group I normal control 
   The slide on normal control (Figure 2) shows presence of 
cell compactness and there is no cell integrity. The islet 
boundaries are clear and the profiles of the islet cells are 
clearly visible. The duct area is prominent without necrosis 
or fatty degeneration observed. The acinar cells are stained 
strongly and found to be arranged in lobules with prominent 
nuclei. The islets cells were found to be embedded in 
among the acinar cells. The overall architecture was found 
to be normal and healthy.
Figure 2. Normal control.
3.7.2. Group II diabetic control
   Cell size was found to be shrunken and severe 
architectural disarray or damage which was observed along 
with absence of islets cells (Figure 3). The pancreatic cell 
degradation is prominent in this slide. The cell integrity is 
total loss. Significant fatty layer degradation has occurred. 
Normal eco-structure has been lost, and central lobes are 
destroyed; normal cellular integrity is completely lost. 
Irregular gap junctions appeared, coagulation occurred 
due to necrosis. The cell disarrangement and architectural 
damage seem to be due to the induction of streptozotocin. 
The photomicrograph also revealed infiltration of 
lymphocytes indicating severe damage.
Figure 3. Diabetic control.
3.7.3. Group III 
   Fatty layers degradation has noticed. The duct area is 
prominent and ballonic present. The compactness of cells 
is comparatively better than diabetic control (Figure 4). In 
most portions cellular integrity is normal with slight fatty 
degeneration. Disarrangement of architecture was observed 
without islets cells around with some artifacts of fixation. 
The remaining acinar cells were observed to be normal as 
compared positive control group.
 Figure 4. Test control (low dose).
3.7.4. Group IV
   The architecture of cells were reverted back to normal 
with  a large proportion of islets cells observed in good 
health. The acinar cell arrangements were found to be 
normalized sufficiently as compared to positive control 
group (Figure 5).
 Figure 5. Test control (high dose).
3.7.5. Group V standard drug treated
   The islets cells in standard drug treated group were 
observed as normal in position. But number of islets cells 
were seems to be less comparative to the normal group. The 
architecture of acinar cells and size were back to normal 
upon the standard drug treatment. The overall cellular 
arrangement were found to be normalized (Figure 6).
 Figure 6. Standard control.
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4. Discussion 
   The study was undertaken to evaluate antihyperglycemic 
effect of MECB in normal controls, STZ-induced untreated 
and treated diabetic rats.
   Diabetes mellitus is mainly caused by the islet 
dysfunction and insulin resistance[24]. It is a group of 
metabolic diseases, and divided into two categories: 
type 1 and type 2. These two types of diabetes have a 
distinct pathogenesis, but hyperglycemia and various 
life-threatening complications resulting from long-term 
hyperglycemia are their most common features. More 
than 90% of diabetic patients are type 2 diabetes suffering 
from severe insulin resistance[25]. From OGTT it could 
be concluded that dose 500 mg/kg showed maximum 
improvement in glucose tolerance. STZ significantly 
induced hyperglycaemia. Oral administration of MECB for 
15 d caused a significant decrease in blood glucose levels. 
The possible mechanism by which MECB mediated its 
antidiabetic effect could suppress hepatic gluconeogenesis 
and glucose output from liver. The hypoglycaemic of MECB 
was compared with metformin, a standard hypoglycaemic 
drug. From the present study it may be suggested that the 
mechanism of action of MECB may be similar to metformin 
action. The patient with diabetes or diabetic animal model 
exhibited the attenuation of antioxidant capacity and/or 
immune function, and then disturbed lipid metabolism 
function[26]. The results in this study indicated that there 
was apparent reduction of serum levels of triglyceride, total 
cholesterol, LDL in treated groups whereas the HDL level 
increased. Elevation of biomarker enzymes such as SGOT, 
SGPT, ALP were observed in diabetic group which indicated 
hepatic damage. On treatment with MECB the reduced 
levels of the elevated marker enzymes i.e. SGOT, SGPT, ALP 
had been restored to more or less normal values which 
indicated recovery of insulin secretion. Hence MECB may 
act as an antihyperglycemic agent. It is widely believed 
that catalase  and glutathione are the important enzymes of 
scavenging oxygen free radicals in organism, and protect 
the pancreatic tissue against oxidative stress injury. In 
addition, the content of malondialdehyde reflects the degree 
of the organic lipid peroxides and cell damage. Our data 
found that the MECB could improve catalase and gluthione 
activities in pancreatic tissue of diabetic mice and lower 
the malondialdehyde content, noting that MECB treatment 
had beneficial effects on diabetes by directly scavenging 
free radical. The pathological examination of the pancreatic 
section using helium-staining exhibited that the islet in the 
normal control group displayed the complete structure and 
uniform arrangement with numerous pancreatic beta cells. 
Normal compactness was found. In contrast, pathology 
of islet in diabetic control group showed damaged with 
loosening or deforming, and the reduction of pancreatic 
beta cells. Severe architectural disarray or damage was 
observed. The structure of islet was partially improved and 
then number of pancreatic beta cells was augmented in low 
dose treated group (250 mg/kg b.w.). The islet structure was 
clearer restoring and the quantity of pancreatic beta cells 
was gradually increased in high dose treated group (500 
mg/kg b.w.). The islets cells of group treated standard drug 
were observed as normal in position. But number of islets 
cells seems to be less comparative to the normal group. The 
architecture of acinar cells and size were back to normal 
upon the standard drug treatment.
   Thus the significant antihyperglycemic activity of 
C. bejolghata could be due to the presence of various 
phytoconstituents detected in the phytochemical screening. 
From the study, it can be concluded that MECB has 
beneficial effect on blood glucose level. It has potential 
to impart therapeutic effect on diabetes. Further studies 
are necessary to elucidate in detail the mechanism of 
action of this medicinal plant at cellular and molecular 
level. It is also necessary to isolate responsible active 
constituents to establish its mechanism of action. It is 
clear from the studies that the plant possesses promising 
antidiabetic activities, so, furthermore studies are required 
for establishing this important plant as a potent source for 
medicinal use.
   The present  data suggested that  MECB has an 
antihyperglycaemic effect in type-2 diabetic rats. Oral 
administration of MECB to the diabetic rats not only 
significantly lowered the blood glucose levels, but also 
caused improvement in lipid profile and other biochemical 
parameters. Meanwhile, the glucose tolerance and in vivo 
antioxidant status were also improved.
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